Epigenetics Global Market Report 2023 – By Product (Reagents, Enzymes, Instruments, Kits), By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures), By Application (Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications), By End-User (Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organisations, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032 

Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others, and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies. The global viral vectors and plasmid dna market is segmented - 1) By Product: Plasmid DNA, Viral Vectors 2) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications 3) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies The global viral vectors & plasmid dna market size grew from $0.8 billion in 2022 to $0.91 billion in 2023 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the viral vectors & plasmid dna is expected to grow from $1.47 billion in 2027 at a CAGR of 12.6%. The rise in the global incidence of cancer is driving the viral vector and plasmid DNA market. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. According to the American cancer society 2020, an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States.Furthermore, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years. Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k???r??r?t??n, Cell and Gene Therapy Catapult, VGXI and MassBiologics. The unaffordable cost of gene therapies is a major challenge in the viral vectors and plasmid DNA market. The prices of gene therapies range from $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. The companies in the viral vectors and plasmid DNA market are focusing on the launch of viral vector assays to boost gene therapy research. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells and viral vector assays is an investigative procedure on viral vector. For example, in November 2022, PerkinElmer, an American testing laboratories company, announced the launch of its "ready-to-use" adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of diseases. The viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. In January 2020, Cognate Bioservices Inc., a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, which specialised in providing manufacturing services for plasmid DNA and viral vectors, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. North America is the largest region in the viral vectors and plasmid DNA market in 2022. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the global viral vectors & plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vectors & plasmid DNA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Point-of-care (POC) molecular diagnostics refers to tests that detect the presence of specific nucleic acids in a clinical specimen, such as feces, saliva, urine, blood, and tissue. This molecular diagnostic is based on seeing targeted portions of microbial genetic material, DNA or RNA. It is utilized by the healthcare sector to detect emergency usage authorization to diagnose diseases. Point-of-care (POC) molecular diagnostic is used to detection of disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS). The main product and services of point-of-care molecular diagnostics are assays and kits, instruments and analyzers and software and services. Assays and kits refer to the equipment which is used in carrying out analyses such as studying disease pathways. Assays and kits were widely used for detecting rapid and accurate diagnosing and monitoring various diseases. Reverse transcription-polymerase chain reaction (RT-PCR), in situ-hybridization and sequencing are the technologies used in point-of-care molecular diagnostics that are used for diagnosis of diseases such as respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis and hematology. Decentralized labs, hospitals, home care, and assisted living healthcare facilities use point of care molecular diagnostics. The global point of care molecular diagnostics market is segmented - 1) By Product And Service: Assays And Kits, Instruments And Analyzers, Software And Services 2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR), In Situ Hybridization, Sequencing 3) By Application: Respiratory Diseases, Hospital Acquired Infections (HAIs), Cancer/Oncology, Hepatitis, Hematology 4) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities The global point-of-care molecular diagnostics market size grew from $2.8 billion in 2022 to $3.14 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the point-of-care molecular diagnostics market is expected to grow to $4.98 billion in 2027 at a CAGR of 12.2%. The rapid growth in the increasing occurrence of infectious and respiratory diseases is expected to significantly contribute to the growth of the point-of-care molecular diagnostics market. Respiratory infections, such as viruses or bacteria, are caused by microorganisms that influence the respiratory system. These microbes can be transferred through coughing, sneezing, or direct touch. The severity of the respiratory medications includes a variety of inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostic to cure the patient. For instance, in May 2020, an annual Report on MCCD (Medical Certification of Cause of Death) 2020 shows that respiratory system diseases are the second most common cause of death, accounting for 10% of the total medically certified causes of death (88.7%). Furthermore, between 2019 and 2020, the number of deaths caused by respiratory disorders increased from 152,311 to 181,160. Therefore, the rapid occurrence of infectious and respiratory diseases and death will drive the point-of-care-molecular diagnostics market. Major players in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, Qiagen Gmbh, Biocartis NV, Nova Biomedical, Thermo Fisher Scientific, Dickinson and Company, Mesa Biotech Inc., OraSure Technologies Inc., Bio-Rad Laboratories Inc., Sysmex, Siemens Healthineers, Bayer HealthCare Pharmaceuticals LLC, Alere Inc., Lucira Health Inc., Cue Health, OpGen Inc., Binx Health Inc., Molbio Diagnostics Pct Ltd., Genomadix, Visby Medical, QuikPath PTE Ltd., QuantuMDx Group Ltd and Sekisui Medical Co Ltd. Technological innovation is a key trend gaining popularity in the point-of-care molecular diagnostics market. Major companies operating in the point-of-care molecular diagnostics market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation point-of-care molecular diagnostics technologies solutions and related services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, and others to implement on POC devices with features of accelerating analysis times and lowering costs. For instance, in March 2020, Abbott Laboratories, a US-based medical device company, launched the molecular point-of-care test available for detecting new COVID-19 (COVID-19). According to the company, the device shows positive results in five minutes and negative in 13 minutes. This test will run on the ID NOW™ platform with isothermal nucleic acid amplification technology that generates molecular results in minutes. In February 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents, consumables, and software services firm acquired Mesa Biotech for an undisclosed amount. With this acquisition, Thermo Fisher Scientific will expand into molecular diagnostics at the point-of-care by bringing much-needed diagnostics to market on a larger scale. Mesa Biotech is a US-based point-of-care molecular diagnostic company. North America was the largest region in the point-of-care molecular diagnostics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The point-of-care molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diagnostic enzymes refer to the enzymes that are employed directly or as part of an assay system to determine the presence or absence of a variety of compounds, and they are used to detect, diagnose, or predict the development of disease conditions. These enzymes are used in diagnosis because of their substrate selectivity and quantified activity when other proteins are present. The main types of products in the diagnostic enzymes market are carbohydrates, polymerases, nucleases, proteases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include animals, microorganisms, and plants and are used in biocatalysts, diagnostics, pharmaceuticals, research, and biotechnology. The global diagnostic enzyme market is segmented - 1) By Product Type: Carbohydrases, Polymerases And Nucleases, Protease, and Other Product Types 2) By Source: Animals, Microorganisms, and Plants 3) By Application: Biocatalysts, Diagnostics, Pharmaceuticals, Research, and Biotechnology The global diagnostic enzymes market size grew from $3.8 billion in 2022 to $4.02 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global diagnostic enzymes is expected to grow from $5.1 billion in 2027 at a CAGR of 6.1%. The rise in the geriatric population, which increases the patient pool for the diagnosis of chronic diseases, contributed to the growth of the diagnostic enzymes market. The proportion of people above the age of 65 increased globally, and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% by 2050 in Japan. The increase in the ageing population has increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly influencing market growth during this period. According to the World Population Ageing report, there were 727 million people over the age of 65 in 2020, accounting for 9.3% of the global population, and this figure is expected to rise to around 16.0% by 2050.According to the World Health Organization report for 2021, approximately 10 million cancer-related deaths occurred in 2020. Thus, the rise in the geriatric population increases the number of patients for the diagnosis of chronic diseases, which, in turn, drives the diagnostic enzymes market. Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific, and EKF Diagnostic. The high sensitivity of enzymes to temperature and pH levels is expected to limit the diagnostic enzymes market. Enzymes need to be stored at optimum temperatures and are generally stored at -20 degrees Celsius. According to the Worthington Biochemical Corporation, variations in the reaction by one or two degrees in temperature may have a change of 10 to 20% in the result. In enzymatic reactions, this is complicated as enzymes are adversely affected by high temperatures, and are expected to be deactivated at even moderate temperatures. Enzymes are affected by changes in pH, as pH is also a factor in the stability of the enzymes. The changes in temperature and pH levels may decrease the efficiency of the diagnostic enzymes, which, in turn, hampers the growth of the diagnostic enzymes market. The use of machine learning and artificial intelligence is gradually gaining popularity in the enzyme diagnostic market. Artificial intelligence (AI) is the simulation of human intelligence in machines and is programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the enzyme diagnostic market to conduct a detailed analysis of all relevant data, provide insights into the function of enzymes, and allow physicians to understand the key determinants of the relationship between protein structure, function, and evolution, in terms of the catalysis of the reaction steps of an enzyme. For instance, companies such as BioMarker have invested in AI and machine learning for enzyme diagnostics. In June 2020, Codexis, Inc., a US-based protein engineering company and developer of high-performance enzymes, and Alphazyme LLC., a US-based company in the development and manufacture of nucleic acid metabolising enzymes, announced a co-marketing enzyme supply collaboration agreement for the production and co-marketing of enzymes for life science applications, including diagnostics. This collaboration is expected to leverage the experience and industry knowledge of Alphazyme to accelerate the market introduction of Codexis’ portfolio of high-performing life science and diagnostic enzymes while providing Alphazyme with exclusive manufacturing and co-marketing rights to CodeEvolver-improved enzymes. This partnership will allow both companies to jointly promote and sell these enzymes to innovators in life science and diagnostic markets. North America was the largest region in the enzymes market in 2022. Middle East is expected to be the fastest-growing region in the diagnostic enzyme market report during the forecast period. The regions covered in the diagnostic enzymes analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The diagnostic enzymes market consists of sales of acid phosphatase, alanine aminotransferase, cholinesterase, and aspartate aminotransferase. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in the diagnostic enzymes market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The diagnostic enzymes market research report is one of a series of new reports from The Business Research Company that provides diagnostic enzymes market statistics, including global market size, regional shares, competitors with a diagnostic enzymes market share, detailed diagnostic enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic enzymes industry. The diagnostic enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cancer tumor profiling refers to a laboratory test that examines a sample of tumor tissue for specific genes, gene mutations (changes), proteins, or other biomarkers. Tumor profiling can help with treatment planning as well as predicting if cancer will recur or spread to other parts of the body. The main types of cancer and tumor profiling are lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and other cancer types. The different technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, and involve various types of processes such as genomics, proteomics, epigenetics, metabolomics, and others. It is used in several applications, including personalized medicine, diagnostics, biomarker discovery, prognostics, and research applications. The global cancer tumor profiling market is segmented - 1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types 2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies 3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types 4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications The global cancer tumor profiling market size grew from $9.62 billion in 2022 to $11.12 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cancer tumor profiling is expected to grow to $18.18 billion in 2027 at a CAGR of 13.1%. The increasing incidences of cancer across the globe are expected to propel the growth of the cancer and tumor profiling market going forward. Cancer is a disease in which some cells in the body get uncontrollably large and spread to other parts of the body. As the number of cancer cases rises, so does the demand for cancer tumor profiling, which enables doctors to determine the severity of the disease. For instance, according to the World Health Organization (WHO), there are a 19.3 million increase in cancer cases in 2020, with over 10 million fatalities worldwide. Among these new cases, lung and breast cancer accounted for 23.1% of all cancer cases. In addition, according to the International Agency for Research on Cancer (IARC), 1 in 5 individuals will develop cancer during their lifetime, and 1 in 11 women and 1 in 8 men will die from it. Therefore, the increasing incidences of cancer across the globe drive the growth of the cancer and tumor profiling market. Major players in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString, NeoGenomics Laboratories, Lucence Health Inc., ACT Genomics Co. Ltd., Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation (Genomic Health Inc.), Guardant Health, and Foundation Medicine Inc. The increasing research and development activities have emerged as the key trend gaining popularity in cancer and tumor profiling market. Major companies operating in cancer and tumor profiling sector are focused on research and development activities to meet consumer demand and reinforce their position. For instance, in February 2020, QIAGEN N.V, a German company that develops sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research announced the Conformitè Europëenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe as a tool to help identify breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test is a diagnostic assay for the detection of an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and first to allow testing of both DNA from plasma specimens or FFPE tissue. In July 2021, Labcorp, a US-based clinical laboratory-acquired OmniSeq for an undisclosed amount. The acquisition enables Labcorp to expand its array of clinical trial options and diagnostic tests for cancer patients and doctors. OmniSeq is a US-based company involved in solid tumor profiling that controls new sequencing technologies and supports drug development through pharmaceutical services. North America was the largest region in cancer and tumor profiling market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor. The main types of tumor embolization devices are radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents involve gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA) used in the treatment of tumors. The applications involved are cancer tumors and noncancerous tumors that are used by various end-users such as hospitals, cancer treatment centers, intensive care units, and surgical centers. The global tumor embolization devices market is segmented - 1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents 2) By Application: Cancer Tumors, Noncancerous Tumors 3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers The global tumor embolization devices market size grew from $1.44 billion in 2022 to $1.61 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the tumor embolization devices is expected to grow from $2.5 billion in 2027 at a CAGR of 11.6%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the tumor embolization devices market during the forecast period. According to the American Cancer Society, there were about 1.9 million new cases and 608,570 cancer deaths in 2021 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the tumor embolization market over the forthcoming years. Major players in the tumor embolization devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Sirtex Medical Ltd., Merit Medical, Cook Meidical LLC., BTG PLC., Angiodynamics, and Siemens Healthineers. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to advanced therapies and advanced therapy medicinal products. These regulations include changes to equipment approval procedures and other aspects. For instance, the United States Food and Drug Administration is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the tumor embolization devices market growth. Companies in the tumor embolization devices market are increasingly investing in technological advances to provide more efficient devices to consumers. The advances include the emergence of biocompatible, biodegradable, drug-eluting microspheres that provide effective embolization. Bioresorbable microspheres block the blood vessels causing tumors without long-term blockage of the healthy tissue blood vessels. In May 2021, Emboline received an investment of $55 m to develop and launch embolic protection catheters from Matrix Capital Management. In Boston Scientific, a US-based medical device manufacturer, acquired Obsidio Inc. for an undisclosed amount. The acquisition would help Boston Scientific to expand its interventional oncology and embolization portfolio. Obsidio is a US-based developer of Embolization gel. North America was the largest region in the tumor embolization devices market in 2022. Asia-Pacific was the second largest region in the global tumor embolization devices market share. The regions covered in the global tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor embolization devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor embolization devices market consists of sales of radioembolic agents and non-radioactive embolic agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The tumor embolization devices market research report is one of a series of new reports from The Business Research Company that provides tumor embolization devices market statistics, including tumor embolization devices industry global market size, regional shares, competitors with a tumor embolization devices market share, detailed tumor embolization devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor embolization devices industry. This tumor embolization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

NGS-based RNA-sequencing is used to identify and measure the amount of ribonucleic acid (RNA) present in a biological sample at a certain moment, using next-generation sequencing (NGS). The massively parallel sequencing technology known as "next-generation sequencing" (NGS) provides extremely high throughput, scalability, and speed. This approach can ascertain the nucleotide sequence of whole genomes or specific DNA or RNA portions. The main products and services of NGS-based RNA sequencing are sample preparation products, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. Sample preparation products enable DNA or RNA to stick to the sequencing flowcell and enable identification of the sample. Sample preparation entails the procedures required to convert nucleic acid mixtures from biological samples into various types of libraries that are prepared for NGS technologies. Sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing are the technologies. These sequencing techniques are used in expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling and transcriptome epigenetics. NGS-based RNA-sequencing is used by research & academia, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The global NGS based RNA sequencing market is segmented - 1) By Product And Service: Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services, Data Analysis, Storage, and Management 2) By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing 3) By Application: Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics 4) By End User: Research & Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other End Users The global NGS-based rna-sequencing market size grew from $2.22 billion in 2022 to $2.74 billion in 2023 at a compound annual growth rate (CAGR) of 23.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the NGS-based rna-sequencing market is expected to grow to $6.3 billion in 2027 at a CAGR of 23.1%. The growth in precision medicine is driving the NGS-based RNA sequencing market. Precision medicine aids doctors in designing individualized treatment plans and making treatment decisions based on a genetic understanding of the patient's disease. There is a growth in precision medicines for treating severe diseases such as cancer. The NGS-based RNA sequencing helps identify the root cause of disease and prescribe specific precision medicine for treatment. For instance, in September 2021, the Swedish Government invested $21.15 million (SEK 220 million) in the Swedish national infrastructure Genomic Medicine Sweden (GMS), to make it easier to keep integrating precision medicine into Swedish healthcare, ensuring that every person there has to access to more accurate tests and individualized care. Such investments are taking place due to a rise in demand for precision medicines. As the demand for precision medicines increases, the demand for NGS-based RNA sequencing will also increase. Major players in the ngs-based rna-sequencing market are Illumina, Thermo Fischer Scientific, Oxford Nanopore, Agilent Technologies Inc., BGI, PerkinElmer Inc., QIAGEN, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Takara Bio Inc., GENEWIZ Inc., Hamilton Company, Macrogen, and Bio-Rad Laboratories Inc. Strategic Partnership is a key trend in the NGS-based RNA sequencing market. Companies are entering into a partnership with NGS-based RNA sequencing companies to expand in new markets and leverage each other's resources. For instance, in May 2022, The Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services, partnered with multiple industry and academic partners. The partnership aims to improve the capacity to swiftly respond to public health emergencies and develop a novel diagnostic capability that covers all recognized and emerging respiratory RNA viruses in a single test. In March 2020, Illumina Inc., a US-based biotechnology company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function, partnered with IDbyDNA Inc. The partnership aims to give laboratories, and hospitals worldwide access to high-fidelity NGS analysis, interpretation, and reporting capabilities. The alliance hopes to enable the widespread distribution of NGS equipment, library prep, and other reagents. IDbyDNA Inc. is a US-based metagenomics technology company. In April 2021, Agilent Technologies, Inc., a US-based company that serves the life sciences, diagnostics, and applied chemical industries by offering analytical equipment, software, services, and consumables for the entire laboratory workflow, acquired Resolution Bioscience for $695 million. Through this acquisition, Agilent will expand its NGS-based cancer diagnostic capabilities and better meet the demands of the rapidly expanding precision medicine market. Agilent's ability to serve clinical diagnostics and biopharma customers is strengthened by the addition of Resolution Bioscience's liquid biopsy-based diagnostic technologies, which also expands the company's opportunities for growth in the diagnostics and genomics sectors. Resolution Bioscience is a US-based company involved in developing and commercializing next-generation sequencing (NGS)-based precision oncology solutions. North America was the largest region in the NGS-based RNA sequencing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in NGS-based RNA sequencing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the NGS-based RNA sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The NGS-based RNA-sequencing market includes revenues earned by ribosomal RNA (rRNA), transfer RNA (tRNA), long ncRNA and many smaller ncRNAs such as microRNA. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The NGS-based RNA sequencing market research report is one of a series of new reports from The Business Research Company that provides NGS-based RNA sequencing market statistics, including NGS-based RNA sequencing industry global market size, regional shares, competitors with a NGS-based RNA sequencing market share, detailed NGS-based RNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the NGS-based RNA sequencing industry. This NGS-based RNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enzyme refers to a protein that almost usually serves as a biological catalyst. It accelerates a certain chemical reaction in the cell. It is a substance that serves as a catalyst in living things, controlling the speed at which chemical processes take place without undergoing any changes. The main product types of enzymes are asparginase, lipase, protease, nattokinase, chitinase, serratiopeptidase, collagenase, ligase, and others. A protease is an enzyme that catalyzes proteolysis, which breaks proteins down into smaller polypeptides or single amino acids and promotes the formation of new protein products. The enzymes are used for the treatment of leukemia, stomach disorders, antitumor, skin ulcers, gauche disease, Fabry disease, and others and are used by drug manufacturers, hospitals, private clinics, and research laboratories. The global enzyme market is segmented - 1) By Product Type: Asparginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products 2) By Application: Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications 3) By End User: Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories The global enzymes market size grew from $10.25 billion in 2022 to $11.63 billion in 2023 at a compound annual growth rate (CAGR) of 13.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the enzymes is expected to grow from $19.73 billion in 2027 at a CAGR of 14.1%. The growing prevalence of cancer requiring drug-metabolizing enzymes (DMEs) for chemotherapy is expected to drive the growth of the enzyme market in the coming years. The activation of enzymes in the human body help destroy the cancer cells and breaks down the tumor. The expression and function of drug-metabolizing enzymes (DMEs) in cancer patients' tumor tissues and metabolic organs is therefore essential and help patients for whom reaction to anticancer drugs and response to chemotherapy is low. According to the World Health Organization (WHO), 10 million deaths occurred in 2020 due to cancer and about 70% of deaths from cancer occur in low- and middle-income countries. Therefore, the increasing prevalence of cancer that can be cured using therapeutic enzymes is predicted to drive the enzyme market growth. Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, Roche Holdings AG and Codexis Inc. The development of new approaches to treat cancer using enzymes is a key trend gaining popularity in the enzymes market. Major universities and companies are investing in research focusing on evolving new solutions in enzyme therapies for cancer treatment. For example, in August 2020, scientists from McGill University and Osaka University in Japan were able to unlock the behavior of an enzyme involved in the spread of cancer cells by using the CMCF beamline at the Canadian Light Source (CLS) at the University of Saskatchewan. In May 2020, AbbVie Inc., an America-based biopharmaceutical company acquired Allergan plc for $63 billion. This acquisition significantly expands and diversifies AbbVie's revenue base and complements existing leadership positions in Immunology, with Humira and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta. Allergan plc is an Ireland-based pharmaceutical company engaged in the research, development, and manufacture of pharmaceutical and enzyme-based therapeutic products. North America was the largest region in the enzymes market in 2022. The regions covered in the enzymes market analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The enzyme market consists of sales of oxidoreductases, transferases, and hydrolases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The enzymes market research report is one of a series of new reports from The Business Research Company that provides enzymes market statistics, including enzymes industry global market size, regional shares, competitors with an enzymes market share, detailed enzymes market segments, market trends, and opportunities, and any further data you may need to thrive in the enzymes industry. This enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Small animal imaging (in-vivo) refers to the advanced imaging techniques for monitoring cellular activity, pharmacological effects that have been developed, and disease progression in live animals. The small animal imaging (in-vivo) is used to observe, define, and quantify normal and pathologic processes in living animal organs and tissues non-invasively. The main components of small animal imaging (in-vivo) are micro-MRI, optical imaging, nuclear imaging, and other components. Micro-MRI refers to a non-invasive technique that produces detailed 3-dimensional (3D) images of tissues without the use of harmful radiation. The various applications include monitoring treatment response, biodistribution, determining drug/target engagement, cancer cell detection, biomarkers, longitudinal studies, and epigenetics which are used in veterinary clinics, veterinary hospitals, and veterinary institutes and research centers. The global small animal imaging in vivo market is segmented – 1) By Component: Micro-MRI, Optical Imaging, Nuclear Imaging, Other Components 2) By Application: Monitoring Treatment Response, Bio Distribution, Determining Drug or Target Engagement, Cancer Cell Detection, Biomarkers, Longitudinal Studies, Epigenetics 3) By End User: Veterinary Clinics, Veterinary Hospitals, Veterinary Institutes and Research Centers The global small animal imaging (in-vivo) market size grew from $2.28 billion in 2022 to $2.54 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global small animal imaging (in-vivo) is expected to grow to $3.8 billion in 2027 at a CAGR of 10.6%. Growing expenditure for the healthcare sector is expected to propel the growth of the small animal imaging (in-vivo) market going forward. Healthcare expenditure refers to the overall cost of health care (including public and private expenditures) as a percentage of GDP. Rising healthcare expenditure and increasing healthcare awareness, encourage the concept of self-care management where PET equipment is used in techniques such as small animal imaging. For instance, according to data released by the Organisation for Economic Co-operation and Development, a France-based intergovernmental economic organization, in 2020 health spending as a share of GDP jumped to 9.7% across OECD countries, up from 8.8% in 2019. A group of 17 OECD countries suggests that health spending continued to grow strongly in 2021 by around 6%. Therefore, growing expenditure for the healthcare sector is driving the growth of the small animal imaging (in-vivo) market. Major players in the market are Bruker, PerkinElmer, Miltenyi Biotec, Aspect Imaging Ltd., Mediso Ltd., LI-COR Biosciences, Life Technologies Corporation, Trifoil Imaging, Promega Corporation, New England Biolabs, MR Solutions Ltd., General Electric, Sofie Biosciences Inc., Biospace Lab, and Agilent Technologies Inc. Technological advancement is a key trend gaining popularity in the small animal imaging (in-vivo) market. Major companies operating in the small animal imaging (in vivo) market are focused on technological advancement to strengthen their position. For instance, in April 2022, PerkinElmer, Inc., a US-based company engaged in business areas such as diagnostics, life science research, and imaging, launched the Vega imaging system, an automated advanced technology ultrasound platform. The automated technology involves the use of two automated transducers, resulting in easy-to-use technology and generating more consistent results to visualize the pathophysiology of the disease. In August 2021, Rigaku Corporation, a Japan-based global manufacturer and distributor of scientific and industrial instrumentation primarily in X-ray and imaging technologies, acquired MILabs B.V. for an undisclosed amount. With this acquisition, Rigaku enlarged its global life sciences modality business by merging its original X-ray imaging business with MILabs' multi-modality businesses for animals, which included PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment. MILabs B.V. is a Netherland-based company engaged in the development and manufacturing of molecular preclinical imaging systems such as SPECT, PET, CT, and optical imaging systems operating in small animal imaging(in-vivo). North America was the largest region in the small animal imaging (in-vivo) market in 2022. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in small animal imaging (in-vivo) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the small animal imaging (in-vivo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The small animal imaging (in-vivo) market includes revenues earned byPET, X-ray CT, MRI, and SPECT scanners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The small animal imaging(in-vivo)market research report is one of a series of new reports from The Business Research Company that provides small animal imaging(in-vivo)market statistics, including small animal imaging(in-vivo)industry global market size, regional shares, competitors with a small animal imaging(in-vivo)market share, detailed small animal imaging(in-vivo)market segments, market trends and opportunities, and any further data you may need to thrive in the small animal imaging(in-vivo)industry. This small animal imaging(in-vivo)market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.